Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort.
Trédan O, Toulmonde M, Le Tourneau C, Montane L, Italiano A, Ray-Coquard I, De La Fouchardière C, Bertucci F, Gonçalves A, Gomez-Roca C, You B, Attignon V, Boyault S, Cassier PA, Dufresne A, Tabone-Eglinger S, Viari A, Sohier E, Kamal M, Garin G, Blay JY, Pérol D.
Trédan O, et al. Among authors: le tourneau c.
Cancers (Basel). 2023 Jun 30;15(13):3441. doi: 10.3390/cancers15133441.
Cancers (Basel). 2023.
PMID: 37444551
Free PMC article.